Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation

Eur J Pharmacol. 2007 Mar 22;559(2-3):210-8. doi: 10.1016/j.ejphar.2006.11.080. Epub 2006 Dec 16.

Abstract

Prostanoid production depends on the activity of two cyclooxygenase (COX) isoforms. It is appreciated that COX-1 plays a role in physiological processes, whereas COX-2 acts in pathological conditions. However their roles, particularly roles of COX-1, have not yet been fully established in inflammation. Here, we examined the effects of COX inhibitors, having differential isoform selectivity, on the late phase of rat carrageenin-induced pleurisy to elucidate the role of COX-2 expressed in the draining lymph nodes and found substantial contribution of COX-1-product(s). Protein and mRNA of COX-2 were detectable with Western blotting analysis and reverse-transcription polymerase chain reaction (RT-PCR) analysis in parathymic lymph nodes, peaking at 48 h after induction of pleurisy. Microsomal prostaglandin E synthase (mPGES)-1 was detectable by immunohistochemical analysis in cells with dendritic processes, a morphological characteristic similar to that of COX-2 expressing cells. Although aspirin, indomethacin and a COX-1 inhibitor, ketorolac, significantly decreased the volume of pleural exudate, they did not affect the levels of COX-2 and mPGES-1 in the lymph node 24 h after induction of pleurisy. In contrast, COX-2 inhibitors, nimesulide and NS-398, had no effect on the exudate volume, but they increased the number of COX-2- and mPGES-1-expressing cells and extension of their dendritic processes with significant increase in the COX-2 level, which were antagonised by ketorolac. These results suggest that COX-2-expressing cells may negatively self-regulate their functions by producing PGE2 via mPGES-1: migration into the draining lymph node and their differentiation. Moreover, COX-1- and COX-2-derived prostanoids may play differential or sometimes antagonistic roles in the late phase of acute inflammation.

MeSH terms

  • Acute Disease
  • Animals
  • Blotting, Western
  • Carrageenan
  • Cyclooxygenase 1 / metabolism*
  • Cyclooxygenase 2 / biosynthesis*
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Cyclooxygenase Inhibitors / pharmacology
  • Cyclooxygenase Inhibitors / therapeutic use
  • Dinoprostone / metabolism
  • Disease Models, Animal
  • Enzyme Induction / drug effects
  • Lymph Nodes / drug effects
  • Lymph Nodes / enzymology*
  • Lymph Nodes / metabolism
  • Lymph Nodes / pathology
  • Male
  • Membrane Proteins / antagonists & inhibitors
  • Membrane Proteins / metabolism*
  • Pleural Effusion / chemically induced
  • Pleural Effusion / drug therapy
  • Pleural Effusion / enzymology*
  • Pleural Effusion / pathology
  • Pleurisy / chemically induced
  • Pleurisy / drug therapy
  • Pleurisy / enzymology*
  • Pleurisy / pathology
  • Prostaglandin-E Synthases
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Prostaglandins / metabolism*
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Reverse Transcriptase Polymerase Chain Reaction
  • Time Factors

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Membrane Proteins
  • Prostaglandins
  • RNA, Messenger
  • Carrageenan
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Ptgs1 protein, rat
  • Ptgs2 protein, rat
  • Prostaglandin-E Synthases
  • Ptges protein, rat
  • Dinoprostone